scispace - formally typeset
Search or ask a question
Author

Su Chu

Bio: Su Chu is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: Chronic myelogenous leukemia & Imatinib mesylate. The author has an hindex of 18, co-authored 30 publications receiving 1869 citations. Previous affiliations of Su Chu include University of Alabama & University of Alabama at Birmingham.

Papers
More filters
Journal ArticleDOI
TL;DR: HDRACi treatment represents an effective strategy to target LSCs in CML patients receiving tyrosine kinase inhibitors and inhibited genes regulating hematopoietic stem cell maintenance and survival.

250 citations

Journal ArticleDOI
17 Nov 2011-Blood
TL;DR: It is demonstrated that BCR-ABL(+) stem cells persist in CML patients despite prolonged treatment with imatinib, and support ongoing efforts to target this population.

236 citations

Journal ArticleDOI
01 Mar 2005-Blood
TL;DR: It is concluded that BCR-ABL kinase mutations can be detected in CD34+ cells from CML patients in CCR on imatinib, may contribute to persistence of small populations of malignant progenitors, and could be a potential source of relapse.

226 citations

Journal ArticleDOI
15 Apr 2004-Blood
TL;DR: It is concluded that inhibition of BCR/ABL kinase activity in CML progenitors by imatinib results in a growth factor-dependent compensatory increase in MAPK activity and in only partial inhibition of PI-3 Kinase activity.

169 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients.
Abstract: BACKGROUND: The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa ...

3,351 citations

Journal ArticleDOI
19 Jan 2012-Nature
TL;DR: The inherently Darwinian character of cancer is the primary reason for this therapeutic failure, but it may also hold the key to more effective control.
Abstract: Cancers evolve by a reiterative process of clonal expansion, genetic diversification and clonal selection within the adaptive landscapes of tissue ecosystems. The dynamics are complex, with highly variable patterns of genetic diversity and resulting clonal architecture. Therapeutic intervention may destroy cancer clones and erode their habitats, but it can also inadvertently provide a potent selective pressure for the expansion of resistant variants. The inherently Darwinian character of cancer is the primary reason for this therapeutic failure, but it may also hold the key to more effective control.

2,575 citations

Journal ArticleDOI
TL;DR: This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors, and discusses the current challenges in the field.
Abstract: Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiological constraints on growth and survival. To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small molecule inhibitors for a host of other kinases that are implicated in cancer and other diseases. Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations. This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.

2,420 citations

Journal ArticleDOI
08 Aug 2013-Blood
TL;DR: Optimal responders to chronic myeloid leukemia treatment should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved.

1,679 citations

Journal ArticleDOI
TL;DR: Imatinib should be continued indefinitely in optimal responders and second-generation TKIs are recommended, followed by allogeneic hematopoietic stem-cell transplantation only in instances of failure and, sometimes, suboptimal response, depending on transplantation risk.
Abstract: Purpose To review and update the European LeukemiaNet (ELN) recommendations for the management of chronic myeloid leukemia with imatinib and second-generation tyrosine kinase inhibitors (TKIs), including monitoring, response definition, and first- and second-line therapy. Methods

1,255 citations